Montelukast Sodium is a potent, selective, anti-inflammatory CysLT1 receptor antagonist (IC50 < 5nM) with no appreciable affect on the CysLT2 receptor. In rat colitis Montelukast Sodium has demonstrated the ability to increase PGE2 (Prostaglandin E2 - sc-201225) production and lower COX-2 expression. Inhibition is competitive with respect to leukotrienes - particularly LTD4, a biologically active mediator that plays an important role in the control of several biochemical pathways involving pulmonary and immune system function.
Contact Information
9 Squares Building, Monalisha Township
Near Zanzarda Chowkdi, Junagadh 362001 (Gujrat, India)
Structure
Product Description
| Details | |
|---|---|
| Chemical Name | MONTELUKAST SODIUM |
| IUPAC Name | sodium 2-[1-[[(1R)-1-[3-[(E)-2-(7-chloroquinolin-2-yl)ethenyl]phenyl]-3-[2-(2-hydroxypropan-2-yl)phenyl]propyl]sulfanylmethyl]cyclopropyl]acetate |
| CAS Number | 151767-02-1 |
| Molecular Formula | C35H35CINO3S.NA |
| Synonyms | mk-476;MK-476-d6;singulair;MONTELUKAST NA;MK-476, Singulair;Motelukast SodiuM;MONTELUKST SODIUM;MONTELUKAST SODIUM;Montelukast SoudiuM;Montelukast SodiuM USP |
| Application | A potent and highly selective CysLT1 receptor antagonist, without demonstrated CysLT2 activity |